Cephalotaxane diterpene synthetase as well as preparation method and application thereof

Through the catalyzing of geranyl pyrophosphate by the novel tristinane diterpene synthase, the problem of unsolved endangered plant resources and biosynthesis pathways has been solved, and the efficient biosynthesis of tristinane diterpene compounds and the development of tumor cells has been achieved. Suppression effect.

CN119082198APending Publication Date: 2024-12-06CAS CENT FOR EXCELLENCE IN MOLECULAR PLANT SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310658493.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-05
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing technology is difficult to effectively synthesize trisine diterpene compounds, resulting in an increase in the pressure on endangered plant resources and the biosynthesis pathway has not been analyzed in depth.

Method used

By digging out the genomic information of the genus Trisphalot-12(13)-ene, the new trisphalot-12(13)-ene were isolated and applied to catalyze the formation of geranium pyrophosphate into diterpene parent nucleus compounds, such as cephalot-12(13)-ene, further forming Hainan crude Trerelactone, using genetic engineering and cell expression techniques to achieve biosynthesis in vitro or in vivo.

Benefits of technology

The efficient biosynthesis of tristinane diterpene compounds was achieved, reducing dependence on endangered plants, providing an efficient and stable source of drugs, and demonstrating a significant inhibitory effect on a variety of tumor cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004267967340000131
    Figure BDA0004267967340000131
  • Figure BDA0004267967340000141
    Figure BDA0004267967340000141
  • Figure BDA0004267967340000151
    Figure BDA0004267967340000151
Patent Text Reader

Abstract

The invention provides cephalotaxane diterpene synthetase as well as a preparation method and application thereof. The cephalotaxane diterpene synthetase is separated for the first time, and geranyl geranyl pyrophosphate (GGPP) can be catalyzed to generate a cephalotaxane cephalot-12 (13)-ene compound product.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of synthetic biology and pharmaceutical technology, and in particular to a novel diterpene cyclase, a microorganism for synthesizing a novel cephalotaxane diterpene skeleton, a preparation method thereof and an application thereof. Background Art

[0002] There are 7 species and 3 varieties of Cephalotaxus in China, 6 of which are endemic. However, as traditional Chinese medicine, some of these species are considered endangered due to interference from human activities and the long development period or low regeneration rate of seeds in the wild.

[0003] A variety of compounds have been discovered from these species, including alkaloids, essential oils, lignans, phenylpropanoids, terpenoids, and flavonoids. Notably, these compounds exhibit antitumor, antiviral, antioxidant, antimicrobial, antibacterial, anti-inflammatory, and antihyperglycemic activities and have been used as parasiticides and plant growth inhibitors.

[0004] As a national protected plant, Cephalotaxus truncatus is an endangered species. At present, the methods for obtaining plant compounds include plant extraction, chemical synthesis, cell tissue culture and plant endophytic fungi. However, in many species of Cephalotaxus, plant secondary metabolites are strictly regulated in plants, resulting in very low content in plants, and the long growth cycle of plants and the long extraction process have limited the development of plant extraction technology. Although the chemical synthesis process is very mature and has low production costs, it has the advantage of saving resources; however, the chemical synthesis reaction conditions are difficult to control, the products are complex, and the pollution problems generated during the synthesis process have yet to be solved. Plant cell tissue culture has the advantage of expanding the source of drugs, but the culture cycle is relatively long, the synthesis capacity is low and unstable. The mechanism of action between endophytic fungi and host plants is still unclear and is in its infancy. At present, some medicinal or industrial ingredients are mainly produced by extracting their active ingredients from Cephalotaxus plants, which has put certain pressure on the wild resources and cultivation of Cephalotaxus plants.

[0005] With the rapid development of molecular biology, biochemistry, chemical analysis methods, and emerging omics and synthetic biology technologies, relying on the analysis of the biosynthetic pathways of medicinal active ingredients, deeply exploring the functional genes related to the biosynthetic pathways of medicinal active ingredients, and using synthetic biology to produce effective ingredients is of great significance for alleviating the pressure on rare and endangered plant resources.

[0006] There is currently no literature report on the analysis of the biosynthetic pathway related to cephalotaxane diterpenes in this field, so effective exploration is urgently needed in this field to clarify the biosynthetic pathway of this type of compound. Summary of the invention

[0007] The purpose of the present invention is to provide a novel cephalotaxane diterpene synthase and its application.

[0008] In the first aspect of the present invention, a method for preparing a diterpene core compound (i.e., a compound having a diterpene core structure, such as cephalot-12(13)-ene) is provided, comprising: using cephalotane diterpene synthase (CS) to catalyze geranylgeranyl pyrophosphate (GGPP) to produce a diterpene core compound product; wherein the cephalotane diterpene synthase is an enzyme having an amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 or a conservative variant protein thereof.

[0009] In one or more preferred embodiments, the conservative variant protein includes: (a) a derived protein formed by replacing, deleting or adding one or more (such as 1-30 or 1-20; preferably 1-15; preferably 1-10; preferably 1-5, 1-3 or 1-2) amino acid residues of the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, and having the catalytic function; (b) an amino acid sequence that is more than 80% (preferably more than 85%, more than 90% or more than 95%; such as more than 98% or more than 99%) identical to the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 and having the catalytic function; or (c) a protein formed by adding a tag or signal peptide sequence to the N or C terminus of the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2.

[0010] In one or more preferred embodiments, the conservative variant protein of the cephalotane diterpene synthase includes: a variant protein corresponding to the amino acid sequence shown in SEQ ID NO:1, with a C to G mutation at position 833, a V to F mutation at position 718, and an M to F mutation at position 627, and the enzyme with the amino acid sequence shown in SEQ ID NO:1 or the variant protein is used to prepare cephalot-12(13)-ene.

[0011] In one or more preferred embodiments, the conservative variant protein of the trihalomethane diterpene synthase includes: a variant protein corresponding to the amino acid sequence shown in SEQ ID NO:1, with a mutation from F to V at position 625, and the variant protein is used to prepare one or more diterpene core compounds including (but not limited to): (1R)-verticillia-4(20),7,11-triene, taxadiene, verticillia-3,7,12-triene, verticillia-3,7,12(18)-triene and (1S)-verticillia-4(20),7,11-triene.

[0012] In one or more preferred embodiments, the cephalotaxane diterpene synthase or its conservative variant protein is a protein with a truncated N-terminus; preferably, it corresponds to the protein of the amino acid sequence shown in SEQ ID NO:1, truncated from the 2nd to 54th amino acid residues at its N-terminus, or corresponds to SEQ ID NO:2, truncated from the 2nd to 54th amino acid residues at its N-terminus.

[0013] In one or more preferred embodiments, the method is performed in vitro (eg, by catalyzing a substrate through a chemical reaction) or in a cell (eg, by biosynthesis through genetically engineered cells).

[0014] In one or more preferred embodiments, the method is carried out in a cell; preferably, the cell is a eukaryotic cell or a prokaryotic cell (such as Escherichia coli or Bacillus subtilis); preferably, the eukaryotic cell includes: a plant cell, a fungal cell, an insect cell or a mammalian cell; preferably, the prokaryotic cell includes Escherichia coli; preferably, the plant cell is a tobacco cell, or the fungal cell is a yeast cell (such as Pichia pastoris).

[0015] In one or more preferred embodiments, the cell is a cell containing (including naturally containing or exogenously / heterologously introduced) IPP (isopentenyl pyrophosphate) and DMAPP (dimethylallyl pyrophosphate) synthesis modules.

[0016] In one or more preferred embodiments, the cell containing IPP and DMAPP synthesis modules includes (naturally occurring or exogenous / heterologously introduced): module I (precursor synthesis): including mevalonate (MVA) pathway and / or methylerythritol phosphate pathway (MEP), producing IPP and DMAPP; module II (diterpene nucleus synthesis): using IPP and DMAPP as substrates to produce GGPP (geranylgeranyl pyrophosphate).

[0017] In one or more preferred embodiments, the cell also expresses (preferably exogenously / heterologously introduced): geranylgeranyl diphosphate synthase (GGPPS), cephalotaxane diterpene synthase (CS), or contains a nucleic acid construct encoding the protein.

[0018] In one or more preferred embodiments, the cell (such as a eukaryotic cell, in particular a tobacco cell) further expresses HMG-CoA-reductase (HMGR).

[0019] In one or more preferred embodiments, the cell (such as a prokaryotic cell, specifically in Escherichia coli) also expresses proteins of the MVA pathway and / or the MEP pathway, including proteins selected from: AtoB acetyl-CoA acetyltransferase), MvaS (mevalonyl-CoA synthetase), MvaE (mevalonyl-CoA reductase), Mvk1 (mevalonate kinase), Mvk2 (phosphomevalonate kinase), MvaD (mevalonate pyrophosphate decarboxylase) and Fni (isopentenyl pyrophosphate Δ-isomerase).

[0020] In one or more preferred embodiments, the MVA pathway and / or the MEP pathway naturally occurs in the cell.

[0021] In one or more preferred embodiments, the cell also expresses other proteins of the MVA pathway and / or the MEP pathway or contains a nucleic acid construct encoding the proteins. For example, further recombinant expression in the presence of the naturally occurring proteins / enzymes can increase the amount of the proteins / enzymes involved in the pathway, thereby promoting the corresponding catalytic steps in the pathway.

[0022] In one or more preferred embodiments, the cell is a tobacco cell, and the expression is performed in a tobacco plant.

[0023] In one or more preferred embodiments, the method further comprises the step of isolating a diterpene core compound (such as Cephalot-12(13)-ene) or a cephalotane diterpene compound (such as Harringtonolide) formed therefrom from cells or plants containing the cells.

[0024] In one or more preferred embodiments, the step of isolating the compound from cells comprises: disrupting the cells, extracting with an organic solvent, concentrating and / or drying, and the organic solvent preferably comprises n-hexane.

[0025] In one or more preferred embodiments, the obtained diterpene core compound includes Cephalot-12(13)-ene, which can further form Harringtonolide.

[0026] In another aspect of the present invention, a use of a cephalotaxane diterpene synthase is provided for catalyzing geranylgeranyl pyrophosphate (GGPP) to form a diterpene core compound; wherein the cephalotaxane diterpene synthase is an enzyme having an amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 or a conservative variant protein thereof.

[0027] In another aspect of the present invention, a cephalotaxane diterpene synthase is provided, which is an enzyme having an amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 or a conservative variant protein thereof.

[0028] In one or more preferred embodiments, the enzyme with the amino acid sequence shown in SEQ ID NO: 1 is derived from Cephalotaxus harringtonia;

[0029] In one or more preferred embodiments, the enzyme with the amino acid sequence shown in SEQ ID NO: 1 is derived from Cephalotaxus hainanensis.

[0030] In another aspect of the present invention, a nucleic acid molecule is provided, which encodes the above-mentioned cephalotaxane diterpene synthase.

[0031] In another aspect of the present invention, a nucleic acid construct is provided, comprising the nucleic acid molecule.

[0032] In one or more preferred embodiments, the nucleic acid construct is a vector, such as a cloning vector, an integration vector or an expression vector.

[0033] In another aspect of the present invention, a host cell is provided, which: (1) expresses the above-mentioned cephalotaxane diterpene synthase, or (2) contains the above-mentioned nucleic acid molecule and / or the above-mentioned nucleic acid construct.

[0034] In another aspect of the present invention, the host cell is provided as a cell containing (including naturally containing or exogenously / heterologously introduced) IPP and DMAPP synthesis modules; preferably, the cell containing the IPP and DMAPP synthesis modules includes: Module I (precursor synthesis): including the mevalonate (MVA) pathway and / or the methylerythritol phosphate pathway (MEP), producing IPP and DMAPP; Module II (diterpene nucleus synthesis): using IPP and DMAPP as substrates to produce GGPP (geranylgeranyl pyrophosphate).

[0035] In one or more preferred embodiments, the cell also expresses (preferably exogenously / heterologously introduced): geranylgeranyl diphosphate synthase (GGPPS) or contains a nucleic acid construct encoding the protein; preferably, the cell also expresses HMG-CoA-reductase (HMGR).

[0036] In another aspect of the present invention, a kit for preparing a diterpene core compound is provided, comprising: the above-mentioned cephalotaxane diterpene synthase, or a nucleic acid molecule encoding the enzyme, or a nucleic acid construct containing the nucleic acid molecule; preferably, it also comprises: geranylgeranyl diphosphate synthase (GGPPS), or a nucleic acid molecule encoding the enzyme, or a nucleic acid construct containing the nucleic acid molecule; preferably, it also comprises a nucleic acid molecule expressing HMG-CoA-reductase (HMGR), or a nucleic acid molecule encoding the enzyme, or a nucleic acid construct containing the nucleic acid molecule;

[0037] In another aspect of the present invention, a kit for preparing a diterpene core compound is provided, comprising: any of the host cells described above.

[0038] In one or more embodiments, the kit further comprises a cell culture medium.

[0039] In one or more embodiments, the kit further includes instructions for use describing the method for preparing the diterpene core compound.

[0040] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 , schematic diagram of the predicted reaction pathway for the biosynthesis of cephalotaxane diterpenes.

[0042] Figure 2 GC-MS analysis of heterologous expression products of strains s6070 and s3840 in Nicotiana benthamiana.

[0043] Figure 3 , compound Cephalot-12(13)-ene structure identification (NMR).

[0044] Figure 4 , the inhibitory effect of Harringtonolide treatment on various tumor cell lines (human oral epidermal carcinoma cells KB, HCT-116 cells, HepG2 cells, A-549 cells, Hela cells, SGC-7901 cells).

[0045] Figure 5 , strain sBM2 can ferment and obtain cephalot-12-ene, which is detected by GC-MS.

[0046] Figure 6 Based on the CharCS protein structure predicted by Robetta, the substrate GGPP was molecularly docked with the protein model of CharCS using Auto-dock Vina, and the interaction between the amino acid residue mutations in the active pocket and the substrate was analyzed.

[0047] Figure 7 , Determination of product yield of some mutants transiently expressed in tobacco.

[0048] Figure 8 , and different mutants at the F625 position of CS produced a series of diterpene core compounds. DETAILED DESCRIPTION

[0049] The inventors have obtained a group of novel cephalotaxane diterpene synthases from Cephalotaxus harringtonia and Cephalotaxus hainanensis through extensive research screening and mining of plant genome and transcriptome information. The synthases are isolated from Cephalotaxus harringtonia and Cephalotaxus hainanensis. The cephalotaxane diterpene synthases are capable of catalyzing geranylgeranyl pyrophosphate (GGPP) to produce diterpene nucleus compounds (such as cephalot-12(13)-ene) compound products, which can further generate cephalotaxane diterpene compounds (such as harringtonolide).

[0050] The novel cephalotaxane diterpene synthase isolated from Cephalotaxus harringtonia and Cephalotaxus hainanensis of the present invention has an amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, respectively. The present invention also includes the conservative variant polypeptides (proteins) thereof. The conservative variant polypeptides are also referred to as "variants".

[0051] In the present invention, the "conservative variant polypeptide" refers to a polypeptide that substantially maintains the same biological function or activity as the polypeptide. The "conservative variant polypeptide" may be (i) a polypeptide having one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) substituted, and such substituted amino acid residues may or may not be encoded by the genetic code, or (ii) a polypeptide having a substituent group in one or more amino acid residues, or (iii) a polypeptide formed by fusion of a mature polypeptide with another compound (such as a compound that prolongs the half-life of the polypeptide, such as polyethylene glycol), or (iv) a polypeptide formed by fusion of an additional amino acid sequence to this polypeptide sequence (such as a leader sequence or secretory sequence or a sequence or proprotein sequence used to purify the polypeptide, or a fusion protein formed with an antigen IgG fragment). According to the teachings of this article, these fragments, derivatives and analogs belong to the scope known to those skilled in the art.

[0052] The "conservative variant polypeptide" may include (but is not limited to): a sequence having at least 80% (e.g., at least 90%, 96%, at least 98%, at least 99%) sequence identity with any one of SEQ ID NOs: 1-2 while retaining its biological activity. Herein, the "biological activity" of the cephalotane diterpene synthase generally refers to its ability to specifically catalyze GGPP and produce diterpene nucleus compounds (such as cephalotane-12(13)-ene). Exemplary such variants include biologically active fragments of the enzyme and variants of the enzyme or its biologically active fragments. The meaning of a biologically active fragment of an enzyme refers to a polypeptide that can still maintain all or part of the functions of a full-length enzyme or protein. Typically, the biologically active fragment retains at least 98% or 99% of the activity.

[0053] Appropriate replacement of amino acids is a well-known technique in the art that can be easily implemented and ensures that the biological activity of the resulting molecule is not changed. These techniques have made those skilled in the art realize that, in general, changing a single amino acid in a non-essential region of a polypeptide will not substantially change the biological activity. In a particularly preferred embodiment, the present invention includes a protein or enzyme whose amino acid sequence has at least 98%, at least 99% sequence identity with the enzyme while retaining the biological activity of the enzyme. For example, the variant may also be from a species of the same or similar origin (such as the same plant).

[0054] As a preferred embodiment of the present invention, the cephalotaxane diterpene synthase or its conservative variant protein is a protein with N-terminal truncated; preferably, the protein corresponding to the amino acid sequence shown in SEQ ID NO: 1, truncated from the 2nd to 54th amino acid residues of the N-terminus, or corresponding to SEQ ID NO: 2, truncated from the 2nd to 54th amino acid residues of the N-terminus. Removing the polypeptide fragment can increase the soluble expression of the truncated protein and significantly improve the intracellular expression efficiency, and when applied to the biosynthetic pathway, it can exert better activity.

[0055] As a preferred embodiment of the present invention, the conservative variant protein of the cephalotane diterpene synthase of the present invention includes: a variant protein corresponding to the amino acid sequence shown in SEQ ID NO:1, with a C to G mutation at position 833, a V to F mutation at position 718, and an M to F mutation at position 627, and the enzyme or the variant protein of the amino acid sequence shown in SEQ ID NO:1 is used to prepare cephalotane cephalot-12(13)-ene. Compared with the wild type, the mutant has higher catalytic activity. The cephalot-12(13)-ene can be (but not limited to) used as an intermediate for synthesizing downstream products (such as Hainan crude quercetin compounds).

[0056] As a preferred embodiment of the present invention, the conservative variant protein of the trihalomethane diterpene synthase includes: a variant protein corresponding to the amino acid sequence shown in SEQ ID NO: 1, with a mutation from F to V at position 625, and the variant protein is used to prepare one or more diterpene core compounds including (but not limited to): (1R)-verticillia-4(20),7,11-triene, taxadiene, verticillia-3,7,12-triene, verticillia-3,7,12(18)-triene and (1S)-verticillia-4(20),7,11-triene. This enriches the types of diterpene core compounds, which can play a role as products or as intermediates.

[0057] The present invention also provides a polynucleotide encoding the cephalotaxane diterpene synthase or a variant thereof described herein. The polynucleotide of the present invention can be in the form of DNA or RNA. The DNA form includes cDNA, genomic DNA or artificially synthesized DNA. The DNA can be single-stranded or double-stranded. The DNA can be a coding strand or a non-coding strand.

[0058] As will be appreciated by those skilled in the art, due to the degeneracy of genetic code, a large amount of nucleic acids can be obtained, which all encode enzymes of the present invention. Therefore, when identifying a specific amino acid sequence, those skilled in the art can obtain any number of different nucleic acids by simply modifying the sequence of one or more codons in a manner that does not change the amino acid sequence of the encoded protein. For example, species (e.g. tobacco) preference codons are used to optimize nucleic acid sequences so that the sequence is easier to express in the species.

[0059] The full-length nucleotide sequence of the protein or enzyme of the present invention or its fragment can usually be obtained by PCR amplification, recombination or artificial synthesis. A feasible method is to synthesize the relevant sequence by artificial synthesis, especially when the fragment length is short. Usually, a fragment with a very long sequence can be obtained by first synthesizing multiple small fragments and then connecting them.

[0060] Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant methods. This is usually done by cloning it into a vector, then transferring it into cells, and then isolating the relevant sequence from the host cells after proliferation by conventional methods. The biomolecules (nucleic acids, proteins, etc.) involved in the present invention include biomolecules in isolated form. At present, the DNA sequence encoding the protein of the present invention (or its fragment, or its derivative) can be obtained completely by chemical synthesis. The DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art. In addition, mutations can also be introduced into the protein sequence of the present invention by chemical synthesis.

[0061] Therefore, the present invention also relates to a nucleic acid construct comprising the above-mentioned appropriate DNA sequence and an appropriate promoter or control sequence, the nucleic acid construct usually carries an extrachromosomal element of a gene that is not part of the central metabolism of the cell, and is often in the form of a circular double-stranded DNA molecule. Such elements can be autonomous replication sequences, genome integration sequences, phage or nucleotide sequences, linear or circular single-stranded or double-stranded DNA or RNA obtained from any source, many of which have been joined or recombined into a specific construct that is capable of introducing the promoter fragment and DNA sequence of the selected gene product together with the appropriate 3' non-translated sequence into the cell.

[0062] Examples of nucleic acid constructs include expression vectors and recombinant vectors. These vectors can be used to transform appropriate host cells to enable them to express proteins. Vectors typically contain sequences for plasmid maintenance and for cloning and expressing exogenous nucleotide sequences. The sequences typically include one or more of the following nucleotide sequences: a promoter, one or more enhancer sequences, an origin of replication, a transcription termination sequence, a complete intron sequence containing donor and acceptor splice sites, a sequence encoding a leader sequence for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, a polylinker region for inserting a nucleic acid encoding an antibody to be expressed, and a selectable marker element.

[0063] Transformation of host cells with recombinant DNA can be carried out using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA can be harvested after the exponential growth phase and treated with the CaCl2 method, the steps used are well known in the art. Another method is to use MgCl2. If necessary, transformation can also be carried out by electroporation. When the host is a eukaryotic organism, the following DNA transfection methods can be selected: calcium phosphate coprecipitation method, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.

[0064] The obtained transformant can be cultured by conventional methods to express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, the culture medium used in the culture can be selected from various conventional culture media. Culture is carried out under conditions suitable for the growth of the host cells. After the host cells grow to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.

[0065] The recombinant polypeptide in the above method can be expressed in the cell, on the cell membrane, or secreted outside the cell. If necessary, the recombinant protein can be separated and purified by various separation methods using its physical, chemical and other properties. These methods are well known to those skilled in the art. Examples of these methods include but are not limited to: conventional renaturation treatment, treatment with a protein precipitant (salting out method), centrifugation, osmotic sterilization, ultra-treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography techniques and combinations of these methods.

[0066] The protein or enzyme of the sequence of the present invention can be expressed in a heterologous host. The host is, for example, a bacterial cell, a fungal cell, such as a yeast cell, a mammalian cell, an insect cell and a plant cell. The heterologous host cell used to express the nucleic acid molecule of the present invention is preferably a cell in which the IPP and DMAPP synthesis modules are endogenously present, so that it can produce the precursors IPP and DMAPP for the reaction in which the enzyme of the present invention participates. The precursors IPP and DMAPP are catalyzed by GGPPS to form GGPP, which can be catalyzed by the enzyme of the present invention to produce a diterpene core compound (such as cephalot-12(13)-ene).

[0067] In the cell, the IPP and DMAPP can be the products of MVA or MEP pathways. The MVA pathway is present in higher eukaryotic organisms, such as but not limited to tobacco, yeast, etc. Therefore, in the present invention, it is preferred that the cell / plant body with the MVA pathway exists. In the MVA pathway, acetyl-CoA is the starting substrate, and under the catalysis of acetoacetyl-CoA synthetase, HMG-CoA synthetase and HMG-CoA-reductase (HMGR), other two molecules of acetyl-CoA are used for condensation and reduction to generate the intermediate product mevalonate. Subsequently, through kinase (mevalonate enzyme, phosphomevalonate kinase, mevalonate diphosphate carboxylase) activation and decarboxylation, the IPP and DMAPP are generated.

[0068] As used herein, the "pathway" and "pathway" are used interchangeably.

[0069] As used herein, "heterologous" or "foreign" refers to the relationship between two or more nucleic acid or protein sequences that are derived from different sources. For example, a promoter is heterologous / foreign to a gene of interest if the combination of the promoter and the gene of interest sequence does not normally occur in nature. A particular sequence is "heterologous / foreign" to the cell or organism into which it is inserted.

[0070] In an exemplary embodiment, the coding sequence of the novel cephalotane diterpene synthase of the present invention is introduced into tobacco cells / tobacco plants that endogenously contain IPP and DMAPP synthesis modules, resulting in the isolation of diterpene core compounds (such as cephalot-12(13)-ene) from tobacco leaves.

[0071] The diterpene core compound (such as cephalot-12(13)-ene) of the present invention can further generate cephalotane diterpene compounds (such as harringtonolide).

[0072] Hainan Torrone is a diterpene compound isolated from Cephalotaxus plants, with a unique and complex carbon skeleton and significant anti-tumor activity. Hainan Torrone has significant anti-tumor activity against oral epidermoid cancer cells, HCT-116 colon cancer cells, HepG2 liver cancer cells, A-549 lung adenocarcinoma cells, cervical cancer cells and SGC-7901 gastric cancer cells. The IC of Hainan Torrone against oral epidermoid cancer cells is 50 The value is 40nM, indicating that Hainan Torreya lactone has great drug potential.

[0073] At present, the methods for obtaining Hainan quinoline lactone compounds include plant extraction, chemical synthesis, cell tissue culture and plant endophytic fungi. Hainan quinoline lactone is strictly regulated in plants as a secondary metabolite of plants, resulting in a very low content in plants, and the growth cycle of plants is long, and the extraction process is time-consuming, which limits the development of plant extraction technology. The present invention uses biosynthesis technology for the first time to achieve the production of the precursor nucleus of such compounds.

[0074] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually carried out according to conventional conditions such as those described in J. Sambrook et al., Molecular Cloning Experiment Guide, 3rd Edition, Science Press, or according to the conditions recommended by the manufacturer.

[0075] Materials and methods

[0076] Torreya grandis and Torreya grandis were collected from Shanghai Chenshan Botanical Garden.

[0077] Oligonucleotide primers were purchased from Sangon Biotechnology (Shanghai) Co., Ltd.

[0078] The synthetic optimized sequence was purchased from GenScript Biotech Corp.

[0079] AxyPrep total RNA miniprep kit, polymerase chain reaction (PCR) gel recovery kit, and plasmid extraction kit are all American Axygen products; PrimeScript RT reagent Kit with gDNA Eraser (Perfect Real Time) polymerase kit and polymerase chain reaction (PCR) high-fidelity enzyme PrimeSTAR Max DNA Polymerase are products of Takara Bio (TAKARA) in Japan. Seamless cloning use II One Step Cloning Kit (Nanjing Novogene Biotech Co., Ltd.).

[0080] All restriction endonucleases were from NEB.

[0081] Escherichia coli DH10B, Agrobacterium tumefaciens GV3101 strain, plant Nicotiana benthamiana and pET-28a, pJF25 (a plasmid obtained by modifying pET-21a to make it resistant to apramycin), and pEAQ-HT vectors were used for gene cloning and protein expression. The molecular chaperone plasmid pGro7 was a product of Takara Biotechnology Co., Ltd. of Japan.

[0082] The standard compound geranylgeranyl pyrophosphate (GGPP) was purchased from Sigma-Aldrich; cephalot-12-ene was prepared in the laboratory and confirmed by NMR and MS analysis.

[0083] Other reagents were domestic analytical or chromatographic grade reagents purchased from Sinopharm Chemical Reagent Co., Ltd.

[0084] Arktik Thermal Cycler (Thermo Fisher Scientific) was used for PCR.

[0085] The gas chromatography-mass spectrometry was performed using a Thermo Trace GC ultra-ISQ spectrometer system (Thermo Fisher Scientific).

[0086] Example 1: Novel Cephalotaxane diterpene synthase

[0087] The invention obtains two novel cephalotaxane diterpene synthases CharCS and ChaiCS by mining the transcriptome information of Cephalotaxus harringtonia and Cephalotaxus hainanensis.

[0088] The amino acid sequences of the cephalotaxane diterpene synthase are as follows:

[0089] >CharCS (SEQ ID NO: 1; the underline indicates the N-terminal truncated region)

[0090] M AHVSICSPFKFNVGLPDKSFQYSVNYRAERWLSSKPSTTSVKLLTRPVRKMASFYDSVESSVQSSVESSLQSSVESSVESSVQSSLQTSVESSAQSSIPRRTAGYHADLWDDARLQCLQSPYDEASSYQERADKLVVRIKHMFNRLQDGEISPSAYDTAWVARVPGRDGSHRPQFPQAIKWLLNNQLEDGSWGLKSSFMLCDRLLSTLNSVISLHAWKTGHRQVEQGICFVRENLKSLTDDDISATDFEIIFPALLQKAKSLGLSLPYNLPFIKSLMEERESALTGVSVAQGIPTCMLNTLEGLEESIDWKKIMSFQNKDGSFLSSPASTACVLLHTGDERCFVFLSNLVEKFGGCVPCLYPIDLLERISLVDNIDHLGIGRHFKEEIKVALDYVYRYWSERGIGWGRGSLFPDLNTTALGIRTLRIHGYDVSPDVLKNFKDDHGRFFSCAGQRHIDLRSIVNLFRASDLAFPGEKIMDEARLFASQYLRQSLTTDTILCNQKLYDEIHYVLEYSWHLSISILEIRSYIDAYDDNYAWLRKSLFKLPYLSNSYCLELAKLDFNMVQSLHQRELKLLSSWWKESGLAQVEFARQRLAEVYFSVATFDLEYSYCRIAFAKIGCLQFF M DDMYDTYGTLEELRTFTEAVKRWDTSLMDKLPDYMQVCYKVWYEAMDEINREVKKIQGRDMMNHIRKSWEMYLGAYMQEREWHETLYIPT V EEYLNTYRISVGLGPCSLQPILVMGEPVTDDDLLKVHYPSRMFYLVSLTWRLTNDTKTSQAEKDRGQVASSVVCYLKENPGCTEEDAQRHFAEIVDEGLKELNFVYLKSDGSPS C CKKFMFNMRQCVQLIYKYRDGYGIATGETKDYIRKALIDPVQV*

[0091] >ChaiCS(SEQ ID NO:2;下划线为N端截短区)

[0092] M AHVSICSPFKFNVGLREKSFQYSVNYRAERWLSSKPSTTSVKLLTRPARMMAS*

[0093] The two novel cephalotaxane diterpene synthases were recombinantly expressed and their functions were verified in vitro in the subsequent Example 2.

[0094] Example 2: Production of Cephalotaxane Using Cephalotaxane Diterpene Synthase

[0095] 1. Reaction pathway of biosynthesis of cephalotaxane

[0096] In this example, the reaction pathway for biosynthesis of cephalotaxane compounds is as follows: Figure 1 .

[0097] The reaction pathway mainly includes:

[0098] (1) IPP and DMAPP produced by the MEP and MVA pathways;

[0099] (2) DMAPP and IPP are condensed to form the diterpene precursor GGPP via geranylgeranyl diphosphate synthase (GGPPS);

[0100] (3) Diterpene synthase CS converts the diterpene precursor GGPP into cephalotaxane.

[0101] The rate-limiting step of the MVA pathway is the catalytic stage of hydroxymethylglutaryl (HMG)-CoA-reductase (HMGR), and the expression of this enzyme can be enhanced.

[0102] 2. Construction of tobacco transient protein expression plasmid

[0103] The artificially synthesized gene sequence was constructed into the pET28a vector to obtain pET28a-ScHMGR, pET28a-TcGGPPS, pET28a-CharCS, and pET28a-ChaiCS, respectively.

[0104] in,

[0105] ScHMGR1: GenBank accession number CAD6640909.1;

[0106] TcGGPPS: GenBank accession number QUF98547.1;

[0107] CharCS is derived from the Torreya grandis transcriptome NCBI accession number PRJNA948641;

[0108] ChaiCS is derived from the transcriptome of Torreya grandis L. (NCBI accession number SRR1509462).

[0109] The PCR primers used to construct the tobacco transient protein expression plasmid of the gene related to cephalotaxane synthesis are shown in Table 1.

[0110] Table 1

[0111]

[0112] Using pET28a-ScHMGR as template and HMGR-F / HMGR-R as primer pair, the ScHMGR fragment was amplified and ligated with the pEAQ-HT vector double-digested with XhoI / SmaI to obtain ptHMGR.

[0113] Using pET28a-TcGGPPS as template and GGPPS-F / GGPPS-R as primer pair, TcGGPPS fragment was amplified and ligated with pEAQ-HT double-digested with XhoI / SmaI to obtain ptGGPPS.

[0114] Using pET28a-CharCS as template and TPS6070-F / TPS6070-R as primer pair, CharCS fragment was amplified and ligated with pEAQ-HT double-digested with XhoI / SmaI to obtain plasmid p6070.

[0115] Using pET28a-ChaiCS as template and TPS3840-F / TPS3840-R as primer pair, the ChaiCS fragment was amplified and ligated with pEAQ-HT double-digested with XhoI / SmaI to obtain plasmid p3840.

[0116] The obtained plasmid was used for transient protein expression in Nicotiana benthamiana.

[0117] 3. Construction of Nicotiana benthamiana for producing cephalotaxane

[0118] The successfully constructed ptHMGR, ptGGPPS, p6070 and p3840 were transformed into competent cells of Agrobacterium GV3101 to obtain expression strains, which were named sHMGR, sGGPPS, s6070 and s3840 respectively. Use LB solid medium (kanamycin 50μg / mL, gentamicin 25μg / mL, rifampicin 25μg / mL) to culture at 30℃ for 48h. Pick a single Agrobacterium clone into 2mL LB liquid medium (kanamycin 50μg / mL, gentamicin 25μg / mL, rifampicin 25μg / mL), shake culture for 24h, transfer 50μL of overnight cultured bacterial solution to new 20mL LB liquid medium (kanamycin 50μg / mL, gentamicin 25μg / mL, rifampicin 25μg / mL) and shake culture at 30℃ for 10h until OD 600 The value of OD was 1, centrifuged at 5000g for 15 min to collect the bacteria, washed with resuspension solution (10mM MgCl2, 10mM MES, 0.2mM acetosyringone) to remove antibiotics and culture medium, centrifuged at 5000g for 15 min to collect the bacteria, and resuspended the bacteria. sHMGR, sGGPPS, s6070 or s3840 were mixed in equal proportions, and the final OD was 1. 6001, placed at room temperature for 2 hours and then injected into tobacco, the infection solution was loaded into a 1 ml syringe and the liquid was injected into the tobacco leaf from the lower epidermis of the leaf. 5 days after the injection, 0.5 g of the tobacco leaf was sampled and ground with liquid nitrogen and 0.5 mL of n-hexane was added to it for extraction 3 times, the residue obtained by concentrating the organic phase was dissolved with 100 μL of n-hexane and 1 μL was taken for GC-MS analysis.

[0119] The presence of cephalotaxane and unconverted GGPP in leaves of Nicotiana benthamiana was detected. Figure 2 The product was separated and purified and then analyzed by mass spectrometry.

[0120] GC-MS and NMR ( Figure 3 ) determined its structure to be cephalot-12(13)-ene (the left structural formula below). Figure 1 , the cephalot-12(13)-ene further forms the harringtonolide (the structural formula on the right below) Hainan crude harringtonolide (CAS No. 64761-48-4):

[0121]

[0122] Harringtonolide was used to treat various tumor cell lines (human oral epidermal carcinoma cell line KB, HCT-116 cells, HepG2 cells, A-549 cells, Hela cells, SGC-7901 cells) and its inhibitory effect was determined. Figure 4 As shown, Harringtonolide has a very significant inhibitory effect on all these tumor cells, among which the inhibition rate on KB cells is the best.

[0123] 4. Construction of heterologous synthetic plasmids in E. coli

[0124] The synthetic gene sequence of the mevalonic acid pathway (MVA pathway) was integrated into the position of the lacY gene of the chromosome of the Escherichia coli BL21 (DE3) strain to ensure sufficient supply of DMAPP / IPP precursors, and strain sZG37 was obtained. The genes used to strengthen the MVA pathway in Escherichia coli include AtoB (WP_077475940.1, from Escherichia coli, acetyl-CoA acetyltransferase), MvaS (WP_002361740.1, from Enterococcus faecalis, mevalonyl-CoA synthetase), MvaE (WP_002382276.1, from Enterococcus faecalis, mevalonyl-CoA reductase), Mvk1 (WP_0001 97034.1, from Staphylococcus aureus, mevalonate kinase), Mvk2 (WP_000616885.1, from Staphylococcus aureus, phosphomevalonate kinase), MvaD (WP_000597335.1, from Staphylococcus aureus, mevalonate pyrophosphate decarboxylase) and Fni (WP_004399098.1, from Bacillus subtilis, isopentenyl pyrophosphate Δ-isomerase).

[0125] The PCR primers used for the construction of E. coli heterologous synthesis plasmids of genes related to cephalotaxane synthesis are shown in Table 2.

[0126] Table 2

[0127]

[0128] Using pET28a-TcGGPPS as template and 21a-GGPPS-F / 21a-GGPPS-R as primer pair, the TcGGPPS fragment was amplified and ligated with pJF25 double-digested with XbaI / SpeI to obtain pMYP100.

[0129] The obtained plasmid was used for heterologous synthesis in E. coli.

[0130] 5. Construction of Escherichia coli producing cephalotaxane

[0131] The successfully constructed pMYP100, pET28a-CharCS and pGro7 were co-transformed into Escherichia coli BL21 (DE3) strain sZG37 to obtain the expression strain named sBM2. After verification, the strain was selected and cloned into 2 ml LB (with kanamycin, apramycin and chloramphenicol), cultured at 37°C, 250 rpm for 12 h, transferred to 100 ml TB (with kanamycin, apramycin and chloramphenicol) at 1% (v / v), and cultured at 37°C, 250 rpm until OD 600About 0.6. Add IPTG (final concentration of 0.1mM), L-arabinose (final concentration of 10mM), 22℃, 250rpm culture for 5d. Take 2ml of bacterial solution and centrifuge, collect the bacteria, add 1ml ddH2O to resuspend, high-pressure ultrasonic crush for 1min, add 1ml ethyl acetate to extract, vortex oscillation, 12000rpm, centrifuge for 20min, take the organic phase and transfer it to a clean EP tube, vacuum concentrate and dry, re-dissolve in 100μL n-hexane, GC-MS test results show that strain sBM2 can ferment cephalot-12-ene, the yield is about 25mg / L ( Figure 5 ).

[0132] Example 3: Construction and activity testing of CS mutant protein

[0133] The inventors further attempted to predict the key sites for interaction with the substrate GGPP through molecular modeling and molecular docking, and to modify these key amino acid residues through site-directed mutagenesis to enhance the catalytic activity of CS.

[0134] 1. Identification of the substrate binding pocket of CharCS

[0135] Based on the CharCS protein structure predicted by Robetta, the inventors used Auto-dock Vina to perform molecular docking between the substrate GGPP and the protein model of CharCS, and found that Q594, F625, F626, M627, M698, E711, V718, R726, S735, R759, T767, S777, C833, M841, I848, and T826 in the active pocket interacted with the substrate, which may be involved in the recognition of GGPP and affect the catalytic efficiency of CharCS ( Figure 6 ). Taking the above into consideration, some sites were mutated into amino acid residues at the corresponding positions of taxadiene synthase (TXS) by site-directed mutagenesis.

[0136] 2. Plasmid and strain construction

[0137] Using p6070 containing wild-type CharCS (from Torreya grandis) as a template, site-directed mutagenesis was performed using the primers shown in Table 3, and the obtained mutants were verified by sequencing to form a recombinant expression plasmid. The recombinant expression plasmid was transformed into Agrobacterium GV3101. The aforementioned strain s6070 containing wild-type CharCS was used as a positive control.

[0138] Using pET28a-CharCS containing wild-type CharCS (codon-optimized for E. coli ) as a template, primer pair 6070-F625x-F / 6070-F625x-R ( Table 3 ) was used to perform saturation mutagenesis on F625, and the obtained mutants were verified by sequencing to construct plasmid pMYPM17-33.

[0139] Table 3. Primers used to construct CharCS mutants

[0140]

[0141] Plasmids pMYPM17-33 were transformed into E. coli BL21 (DE3) strains together with pMYP100 and pGro7 to obtain strains sMYPM17-33. The aforementioned strain sBM2 containing wild-type CharCS (codon-optimized) was used as a positive control.

[0142] 3. Mutant activity test

[0143] The mutants at positions 627, 718, and 833 as shown in Table 3 were co-infected with sHMGR and sGGPPS in Nicotiana benthamiana, and transient expression was performed in tobacco according to the method described in Example 2, and GC-MS detection was performed. After the strains sMYPM17-33 were cultured and the fermentation products were extracted according to the method described in Example 2, GC-MS detection was performed.

[0144] The results showed that in tobacco transiently expressed mutants, M627F, V718F, and C833G could significantly increase the production of cephalot-12-ene, reaching 246%, 252%, and 458% of the wild type, respectively. Figure 7 ).

[0145] In another mutation F625V, although it is unable to produce taxane, it is able to produce a series of other diterpene cores, such as (1R)-verticillia-4(20),7,11-triene, taxadiene, verticillia-3,7,12-triene, verticillia-3,7,12(18)-triene and (1S)-verticillia-4(20),7,11-triene. Figure 8 ), in the saturated mutant series of F625 (sMYPM17~33), the proportions of the corresponding diterpene mother nuclei were different.

[0146] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims. At the same time, all the documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference separately.

Claims

1. A method for preparing a diterpene core compound, include: The geranylgeranyl pyrophosphate is catalyzed by the cephalotaxane diterpene synthase to produce a diterpene nucleus compound product; Wherein, the cephalotaxane diterpene synthase is an enzyme having an amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 or a conservative variant protein thereof.

2. The method according to claim 1, It is characterized in that The conservative variant proteins include those selected from: (a) a protein derived from the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 by substitution, deletion or addition of one or more amino acid residues, and having the catalytic function; (b) a derived protein having an amino acid sequence that is more than 80% identical to the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 and having the catalytic function; or (c) A protein formed by adding a tag or a signal peptide sequence to the N- or C-terminus of the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO:

2.

3. The method according to claim 2, It is characterized in that The conservative variant proteins of the cephalotaxane diterpene synthase include: A variant protein corresponding to the amino acid sequence shown in SEQ ID NO:1, wherein the 833rd position has a C to G mutation, the 718th position has a V to F mutation, and the 627th position has an M to F mutation, and the enzyme with the amino acid sequence shown in SEQ ID NO:1 or the variant protein is used to prepare cephalot-12(13)-ene; or A variant protein corresponding to the amino acid sequence shown in SEQ ID NO:1, wherein a mutation from F to V occurs at position 625, and the variant protein is used to prepare one or more of the following diterpene core compounds: (1R)-verticillia-4(20),7,11-triene, taxadiene, verticillia-3,7,12-triene, verticillia-3,7,12(18)-triene and (1S)-verticillia-4(20),7,11-triene.

4. The method according to any one of claims 1 to 3, It is characterized in that The cephalotaxane diterpene synthase or its conservative variant protein is a protein with a truncated N-terminus; preferably, it corresponds to the protein of the amino acid sequence shown in SEQ ID NO:1, truncated from the 2nd to 54th amino acid residues of its N-terminus, or corresponds to SEQ ID NO:2, truncated from the 2nd to 54th amino acid residues of its N-terminus.

5. The method according to claim 1, It is characterized in that The method is performed in vitro or in cells; Preferably, the method is performed in a cell; preferably, the cell is a eukaryotic cell or a prokaryotic cell; preferably, the eukaryotic cell includes: a plant cell, a fungal cell, an insect cell or a mammalian cell; preferably, the prokaryotic cell includes Escherichia coli; preferably, the plant cell is a tobacco cell, or the fungal cell is a yeast cell; Preferably, the cell is a cell containing IPP and DMAPP synthesis modules.

6. The method according to claim 5, It is characterized in that The cell containing the IPP and DMAPP synthesis module includes: Module I: includes the mevalonate pathway and / or the methylerythritol phosphate pathway, producing IPP and DMAPP; Module II: Using IPP and DMAPP as substrates, GGPP is produced.

7. The method according to claim 5 or 6, It is characterized in that The cell further expresses: geranylgeranyl diphosphate synthase, cephalotaxane diterpene synthase, or a nucleic acid construct encoding the protein; Preferably, the cell also expresses HMG-CoA-reductase; or Preferably, the cell further expresses proteins of the MVA pathway and / or the MEP pathway, including proteins selected from the group consisting of: AtoB, MvaS, MvaE, Mvk1, Mvk2, MvaD and Fni.

8. Application of cephalotaxane diterpene synthase to catalyze the formation of diterpene nucleus compounds from geranylgeranyl pyrophosphate; in, The cephalotaxane diterpene synthase is an enzyme having an amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 or a conservative variant protein thereof; Preferably, the conservative variant protein of the cephalotaxane diterpene synthase includes: A variant protein corresponding to the amino acid sequence shown in SEQ ID NO:1, wherein the 833rd position has a C to G mutation, the 718th position has a V to F mutation, and the 627th position has an M to F mutation, and the enzyme with the amino acid sequence shown in SEQ ID NO:1 or the variant protein is used to prepare cephalot-12(13)-ene; or A variant protein corresponding to the amino acid sequence shown in SEQ ID NO:1, wherein a mutation from F to V occurs at position 625, and the variant protein is used to prepare one or more of the following diterpene core compounds: (1R)-verticillia-4(20),7,11-triene, taxadiene, verticillia-3,7,12-triene, verticillia-3,7,12(18)-triene and (1S)-verticillia-4(20),7,11-triene.

9. A cephalotaxane diterpene synthase, which is an enzyme having an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2 or a conservative variant protein thereof; Preferably, the enzyme with the amino acid sequence shown in SEQ ID NO: 1 is derived from Cephalotaxus harringtonia; Preferably, the enzyme with the amino acid sequence shown in SEQ ID NO: 1 is derived from Cephalotaxus hainanensis.

10. The cephalotaxane diterpene synthase according to claim 9, It is characterized in that The conservative variant proteins of the cephalotaxane diterpene synthase include: A variant protein corresponding to the amino acid sequence shown in SEQ ID NO:1, wherein the 833rd position has a C to G mutation, the 718th position has a V to F mutation, and the 627th position has an M to F mutation, and the enzyme with the amino acid sequence shown in SEQ ID NO:1 or the variant protein is used to prepare cephalot-12(13)-ene; or A variant protein corresponding to the amino acid sequence shown in SEQ ID NO:1, wherein a mutation from F to V occurs at position 625, and the variant protein is used to prepare one or more of the following diterpene core compounds: (1R)-verticillia-4(20),7,11-triene, taxadiene, verticillia-3,7,12-triene, verticillia-3,7,12(18)-triene and (1S)-verticillia-4(20),7,11-triene.

11. The cephalotaxane diterpene synthase according to claim 9 or 10, It is characterized in that The cephalotaxane diterpene synthase or its conservative variant protein is a protein with a truncated N-terminus; preferably, it corresponds to the protein of the amino acid sequence shown in SEQ ID NO:1, truncated from the 2nd to 54th amino acid residues of its N-terminus, or corresponds to SEQ ID NO:2, truncated from the 2nd to 54th amino acid residues of its N-terminus. 12 . A nucleic acid molecule encoding the cephalotaxane diterpene synthase according to claim 9 .

13. A nucleic acid construct comprising the nucleic acid molecule of claim 12; preferably, the nucleic acid construct is a vector, such as a cloning vector, an integration vector or an expression vector.

14. A host cell, the cell: (1) expressing the cephalotaxane diterpene synthase according to claim 9 or 10, or (2) Containing the nucleic acid molecule and / or the nucleic acid construct.

15. The host cell according to claim 14, It is characterized in that The host cell is a cell containing an IPP and DMAPP synthesis module; preferably, the cell containing an IPP and DMAPP synthesis module comprises: Module I: includes the mevalonate pathway and / or the methylerythritol phosphate pathway, producing IPP and DMAPP; Module II: Using IPP and DMAPP as substrates, GGPP is produced.

16. The host cell according to claim 14 or 15, It is characterized in that The cell also expresses: geranylgeranyl diphosphate synthase or contains a nucleic acid construct encoding the protein; preferably, the cell also expresses HMG-CoA-reductase.

17. A kit for preparing a diterpene core compound, wherein include: The cephalotaxane diterpene synthase according to claim 9 or 10, or a nucleic acid molecule encoding the enzyme, or a nucleic acid construct containing the nucleic acid molecule; preferably, further comprising: geranylgeranyl diphosphate synthase, or a nucleic acid molecule encoding the enzyme, or a nucleic acid construct containing the nucleic acid molecule; preferably, further comprising expressing HMG-CoA-reductase, or a nucleic acid molecule encoding the enzyme, or a nucleic acid construct containing the nucleic acid molecule; The host cell according to any one of claims 14 to 16.